Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug

V-ATPase is a candidate therapeutic target for Ewing sarcoma

(2013) Sofia Avnet et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells

(2013) Murielle Mimeault et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Correlation ofTP53andMDM2genotypes with response to therapy in sarcoma

(2012) Hege O. Ohnstad et al.   CANCER

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

(2012) A. Naing et al.   CLINICAL CANCER RESEARCH

Insulin resistance and cancer: epidemiological evidence

(2012) Manami Inoue et al.   ENDOCRINE-RELATED CANCER

Metformin Inhibits Growth of Thyroid Carcinoma Cells, Suppresses Self-Renewal of Derived Cancer Stem Cells, and Potentiates the Effect of Chemotherapeutic Agents

(2012) Guofang Chen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Metformin in cancer: translational challenges

(2012) Ryan J O Dowling et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma

(2012) Cecilia Garofalo et al.   MOLECULAR ENDOCRINOLOGY

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects

(2012) M A Pierotti et al.   ONCOGENE

Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft-tissue Sarcoma committee experience and rationale for current COG studies

(2012) Suman Malempati et al.   PEDIATRIC BLOOD & CANCER

Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning

(2012) Michael N. Pollak   Cancer Discovery

Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer

(2012) Victoria Forte et al.   CardioRenal Medicine

Targeting Tumor Perfusion and Oxygenation to Improve the Outcome of Anticancer Therapy1

(2012) Bénédicte F. Jordan et al.   Frontiers in Pharmacology

Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1

(2011) I. Ben Sahra et al.   CANCER RESEARCH

Metformin Decreases the Dose of Chemotherapy for Prolonging Tumor Remission in Mouse Xenografts Involving Multiple Cancer Cell Types

(2011) D. Iliopoulos et al.   CANCER RESEARCH

Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth

(2011) G. Z. Rocha et al.   CLINICAL CANCER RESEARCH

Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system

(2011) Mari C. Asensio-López et al.   FREE RADICAL BIOLOGY AND MEDICINE

AMP-activated protein kinase--an energy sensor that regulates all aspects of cell function

(2011) D. G. Hardie   GENES & DEVELOPMENT

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study

(2011) Alberto S. Pappo et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling

(2011) C Garofalo et al.   ONCOGENE

Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

(2011) Vivek Subbiah et al.   PLoS One

Heterogeneous Role of the Glutathione Antioxidant System in Modulating the Response of ESFT to Fenretinide in Normoxia and Hypoxia

(2011) Tapiwanashe Magwere et al.   PLoS One

Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor

(2010) Helen J Knowles et al.   BMC CANCER

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

(2010) Mahvash Zakikhani et al.   BREAST CANCER RESEARCH AND TREATMENT

Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation

(2010) Hyung Gyun Kim et al.   BRITISH JOURNAL OF PHARMACOLOGY

Synthetic Lethality Screens Reveal RPS6 and MST1R as Modifiers of Insulin-like Growth Factor-1 Receptor Inhibitor Activity in Childhood Sarcomas

(2010) J. C. Potratz et al.   CANCER RESEARCH

Hypoxia Modulates EWS-FLI1 Transcriptional Signature and Enhances the Malignant Properties of Ewing's Sarcoma Cells In vitro

(2010) D. N. T. Aryee et al.   CANCER RESEARCH

Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, aurorasandpolo-like kinases] M-phase cell cycle genes in human breast cancer cells

(2010) Cristina Oliveras-Ferraros et al.   CELL CYCLE

NVP-BEZ235 as a New Therapeutic Option for Sarcomas

(2010) M. C. Manara et al.   CLINICAL CANCER RESEARCH

Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer

(2010) E. Rozengurt et al.   CLINICAL CANCER RESEARCH

Targeting insulin-like growth factor 1 receptor in sarcomas

(2010) Katia Scotlandi et al.   CURRENT OPINION IN ONCOLOGY

Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer

(2010) M. Bodmer et al.   DIABETES CARE

Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo

(2010) C Algire et al.   ONCOGENE

Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study

(2009) Jonathan L. Wright et al.   CANCER CAUSES & CONTROL

The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma

(2009) R. T. Kurmasheva et al.   CANCER RESEARCH

Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma

(2009) S. Avnet et al.   CANCER RESEARCH

Molecular genetics of sarcomas: Applications to diagnoses and therapy

(2009) Junya Toguchida et al.   CANCER SCIENCE

mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb®)

(2009) Alejandro Vázquez-Martín et al.   Clinical & Translational Oncology

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

(2009) C. J. Currie et al.   DIABETOLOGIA

Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease

(2009) Antonino Belfiore et al.   ENDOCRINE REVIEWS

Antidiabetic Therapies Affect Risk of Pancreatic Cancer

(2009) Donghui Li et al.   GASTROENTEROLOGY

Metformin in Breast Cancer: Time for Action

(2009) Pamela J. Goodwin et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?

(2008) Vuk Stambolic et al.   BREAST CANCER RESEARCH AND TREATMENT